Lactobacillus reuteri against Helicobacter pylori: in vitro and in vivo efficacy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper discusses the evolution of eradication therapy. It emphasizes the efficacy and safety of Helinorm used alone and in combination with standard eradication therapy.

全文:

受限制的访问

作者简介

Yu. Uspensky

Saint Petersburg State Pediatric Medical University; Acad. I.P. Pavlov First Saint Petersburg State Medical University

Email: baryshnikova_nv@mail.ru
Professor; MD

N. Baryshnikova

Acad. I.P. Pavlov First Saint Petersburg State Medical University; Institute of Experimental Medicine

Email: baryshnikova_nv@mail.ru
Candidate of Medical Sciences

参考

  1. Blaser M. Hypothesis: changing relationships of Helicobacter pylori and humans: implications for health and disease // J. Infect. Dis. - 1999; 179 (6): 1523-30.
  2. Cohen H., Gramisu M., Fitzgibbons P. et al. Campylobacter pylori: associations with antral and fundal mucosal histology // Am. J. Gastroenterol. -1989; 84: 367-71.
  3. Hocker M., Hohenberger P. Helicobacter pylori virulence factors - one part of a big picture // Lancet. - 2003; 362 (9391): 1231-3.
  4. Malfertheiner P., Mégraud F., O’Morain C. Guidelines for the Management of Helicobacter Pylori Infection (2005). URL: https://061fb23c-fc26-4745-b739-1ba460436926.filesusr.com/ugd/d8d367_0d02c9a8554c476995c8bd67e47d0eca.pdf (дата обращения 06.12.2019).
  5. Stolte M., Eidit S., Ritter M. et al. Campylobacter pylori and gastritis // Pathologe. - 1989; 10: 21-6.
  6. Uspenskiy Y., Baryshnikova N., Smirnova A. et al. Prevalence of Helicobacter pylori infection in healthy volunteers and duodenal ulcer patients in St.-Petersburg, russia // J. Gastroenterol. Hepatol. - 2010; 25 (Suppl. 3): A43.
  7. Warren J., Marshall B. Unindentified curved bacilli on gastric epithelium in chronic gastritis // Lancet. - 1983; 1 (8336): 1273-5.
  8. Marshall B., Armstrong J., McGechie D. et al. Attempt to fulfil Koch’s postulates for pyloric Campylobacter // Med. J. Australia. - 1985; 142 (8): 436-9.
  9. Marshall B., Armstrong J., Francis G. et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis // Digestion. - 1987; 37 (suppl. 2): 16-30.
  10. Marshall B., McGechie D., Rogers P. et al. Pyloric Campylobacter infection and gastroduodenal disease // Med. J. Australia. - 1985; 142 (8): 439-44.
  11. Ciccaglione A., Cellini L., Grossi L. et al. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study // Helicobacter. - 2015. doi: 10.1111/hel.12209.
  12. George L., Borody T., Andrews P. et al. Cure of duodenal ulcer after eradication of Helicobacter pylori // Med J Aust. - 1990; 153 (3): 145-9.
  13. Iser J., Buttigieg R., Iseli A. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer // Med. J. Aust. - 1994; 160 (4): 192-6.
  14. Wagner S., Varrentrapp M., Haruma K. et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection // Z. Gastroenterol. - 1991; 29 (11): 595-8.
  15. Bazzoli F., Pozzato P. Therapy of H. pylori infection // J. Physiol. Pharmacol. - 1997; 48 (Suppl. 4): 39-46.
  16. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group // Gut. - 1997; 41: 8-13.
  17. Malfertheiner P., Mégraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report // Aliment. Pharmacol. Ther. - 2002; 16: 167-180.
  18. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. - 2007; 56: 772-81. doi: 10.1136/gut.2006.101634.
  19. Malfertheiner P. et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report // Gut. - 2012; 61: 646-64.
  20. Malfertheiner P., Megraud F., O’Morain C. et al. On behalf of the European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report // Gut. - 2017; 66: 6-30. doi: 10.1136/gutjnl-2016-312288.
  21. Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике / СПб: ИнформМед, 2011; с. 497-537
  22. Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике / СПб, ИнформМед, 2011; 497-506
  23. Szajewska H. Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther - 2010; 32: 1069-79.
  24. Molina-Infante J., Gisbert J. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time // Rev. Esp. Enferm. Dig. - 2013; 105 (8): 441-4.
  25. Tong J., Ran Z., Shen J. et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy // Aliment. Pharmacol. Ther. - 2007; 25: 155-68.
  26. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. -2013; 47: 25-32.
  27. Sachdeva A., Nagpal J. Meta-analysis: Efficacy of bovine lactoferrin in Helicobacter pylori eradication // Aliment. Pharmacol. Ther. - 2009; 29: 720-30.
  28. Zou J., Dong J., Yu X. Meta-analysis: The effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy // Helicobacter. - 2009; 14: 119-27.
  29. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials // Eur. J. Gastroenterol. Hepatol. - 2009; 21: 45-53.
  30. Dinleyici E., Kara A., Ozen M. et al. Saccharomyces boulardii CNCM I-745 in different clinical conditions // Expert Opin. Biol. Ther. - 2014; 14: 1593-609.
  31. Козлова Д.И. Состояние кишечного микробиоценоза и течение H. pylori-ассоциированного гастрита в условиях эрадикационной и синбиотической терапии. Автореф. дисс.. канд. мед. наук. СПб, 2004; 21 с.
  32. Canducci F., Cremonini F., Armuzzi A. et al. Probiotics and Helicobacter pylori eradication. // Dig. Liver Dis.: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. - 2002; 34 (suppl. 2): 81-3.
  33. Суворов А.Н., Барышникова Н.В., Сварваль А.В. и др. Возможности некоторых пробиотических штаммов вэ радикации Helicobacter pylori in vitro и in vivo // Фарматека. - 2018; 2 (355): 74-8 DOI: https://dx.doi.org/10.18565/pharmateca.2018.2.74-78.
  34. Holz C., Busjahn A., Mehling H. et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study // Probiotics Antimicrob. Proteins. - 2015; 7 (2): 91-100. doi: 10.1007/s12602-014-9181-3.
  35. Mehling H., Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans // Nutrients. - 2013; 5: 3062-73.
  36. Francavilla R., Polimeno L., Demichina A. et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebocontrolled study // J. Clin. Gastroenterol. - 2014; 48 (5): 407-13. doi: 10.1097/MCG.0000000000000007.
  37. Dore M., Cuccu M., Pes G. et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection // Intern. Emerg. Med. - 2014; 9 (6): 649-54. doi: 10.1007/s11739-013-1013-z.
  38. Muresan I., Pop L., Dumitrascu D. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia // Med. Pharm. Rep. - 2019; 92 (4): 352-5. doi: 10.15386/mpr-1375.
  39. Бордин Д.С., Войнован И.Н., Хомерики С.Г. и др. Эффективность и безопасность пробиотических бактерий Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori, не имеющих абсолютных показаний для эрадикационной терапии: результаты исследования // Лечащий врач. - 2016; 5 URL: https://www.lvrach.ru/2016/05/15436483/ (дата обращения 06.12.2019).
  40. Паролова Н.И., Корниенко Е.А., Антонов П.В. и др. Инновационный подход в терапии инфекции Н. pylori у детей // РМЖ. - 2015; 22: 1339-40
  41. Успенский Ю.П., Фоминых Ю.А., Иванов С.В. и др. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? // РМЖ. - 2016; 17: 1144-52
  42. Успенский Ю.П., Барышникова Н.В., Фоминых Ю.А. Лечение инфекции Helicobacter pylori: проблемы и перспективы // Consilium Medicum. Гастроэнтерология. (Прил.). - 2015; 1: 8-17
  43. Ткаченко Е., Успенский Ю., Барышникова Н. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori // Врач. - 2012; 1: 36-8

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2022
##common.cookie##